Cargando…

Can GPR4 Be a Potential Therapeutic Target for COVID-19?

Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late 2019 and has since rapidly become a global pandemic. SARS-CoV-2 infection causes damages to the lung and other organs. The clinical manifestations of COVID-19 range widely...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li V., Oppelt, Karen A., Thomassen, Mary Jane, Marie, Mona A., Nik Akhtar, Shayan, McCallen, Justin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859652/
https://www.ncbi.nlm.nih.gov/pubmed/33553219
http://dx.doi.org/10.3389/fmed.2020.626796
_version_ 1783646781190438912
author Yang, Li V.
Oppelt, Karen A.
Thomassen, Mary Jane
Marie, Mona A.
Nik Akhtar, Shayan
McCallen, Justin D.
author_facet Yang, Li V.
Oppelt, Karen A.
Thomassen, Mary Jane
Marie, Mona A.
Nik Akhtar, Shayan
McCallen, Justin D.
author_sort Yang, Li V.
collection PubMed
description Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late 2019 and has since rapidly become a global pandemic. SARS-CoV-2 infection causes damages to the lung and other organs. The clinical manifestations of COVID-19 range widely from asymptomatic infection, mild respiratory illness to severe pneumonia with respiratory failure and death. Autopsy studies demonstrate that diffuse alveolar damage, inflammatory cell infiltration, edema, proteinaceous exudates, and vascular thromboembolism in the lung as well as extrapulmonary injuries in other organs represent key pathological findings. Herein, we hypothesize that GPR4 plays an integral role in COVID-19 pathophysiology and is a potential therapeutic target for the treatment of COVID-19. GPR4 is a pro-inflammatory G protein-coupled receptor (GPCR) highly expressed in vascular endothelial cells and serves as a “gatekeeper” to regulate endothelium-blood cell interaction and leukocyte infiltration. GPR4 also regulates vascular permeability and tissue edema under inflammatory conditions. Therefore, we hypothesize that GPR4 antagonism can potentially be exploited to mitigate the hyper-inflammatory response, vessel hyper-permeability, pulmonary edema, exudate formation, vascular thromboembolism and tissue injury associated with COVID-19.
format Online
Article
Text
id pubmed-7859652
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78596522021-02-05 Can GPR4 Be a Potential Therapeutic Target for COVID-19? Yang, Li V. Oppelt, Karen A. Thomassen, Mary Jane Marie, Mona A. Nik Akhtar, Shayan McCallen, Justin D. Front Med (Lausanne) Medicine Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late 2019 and has since rapidly become a global pandemic. SARS-CoV-2 infection causes damages to the lung and other organs. The clinical manifestations of COVID-19 range widely from asymptomatic infection, mild respiratory illness to severe pneumonia with respiratory failure and death. Autopsy studies demonstrate that diffuse alveolar damage, inflammatory cell infiltration, edema, proteinaceous exudates, and vascular thromboembolism in the lung as well as extrapulmonary injuries in other organs represent key pathological findings. Herein, we hypothesize that GPR4 plays an integral role in COVID-19 pathophysiology and is a potential therapeutic target for the treatment of COVID-19. GPR4 is a pro-inflammatory G protein-coupled receptor (GPCR) highly expressed in vascular endothelial cells and serves as a “gatekeeper” to regulate endothelium-blood cell interaction and leukocyte infiltration. GPR4 also regulates vascular permeability and tissue edema under inflammatory conditions. Therefore, we hypothesize that GPR4 antagonism can potentially be exploited to mitigate the hyper-inflammatory response, vessel hyper-permeability, pulmonary edema, exudate formation, vascular thromboembolism and tissue injury associated with COVID-19. Frontiers Media S.A. 2021-01-21 /pmc/articles/PMC7859652/ /pubmed/33553219 http://dx.doi.org/10.3389/fmed.2020.626796 Text en Copyright © 2021 Yang, Oppelt, Thomassen, Marie, Nik Akhtar and McCallen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Yang, Li V.
Oppelt, Karen A.
Thomassen, Mary Jane
Marie, Mona A.
Nik Akhtar, Shayan
McCallen, Justin D.
Can GPR4 Be a Potential Therapeutic Target for COVID-19?
title Can GPR4 Be a Potential Therapeutic Target for COVID-19?
title_full Can GPR4 Be a Potential Therapeutic Target for COVID-19?
title_fullStr Can GPR4 Be a Potential Therapeutic Target for COVID-19?
title_full_unstemmed Can GPR4 Be a Potential Therapeutic Target for COVID-19?
title_short Can GPR4 Be a Potential Therapeutic Target for COVID-19?
title_sort can gpr4 be a potential therapeutic target for covid-19?
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859652/
https://www.ncbi.nlm.nih.gov/pubmed/33553219
http://dx.doi.org/10.3389/fmed.2020.626796
work_keys_str_mv AT yangliv cangpr4beapotentialtherapeutictargetforcovid19
AT oppeltkarena cangpr4beapotentialtherapeutictargetforcovid19
AT thomassenmaryjane cangpr4beapotentialtherapeutictargetforcovid19
AT mariemonaa cangpr4beapotentialtherapeutictargetforcovid19
AT nikakhtarshayan cangpr4beapotentialtherapeutictargetforcovid19
AT mccallenjustind cangpr4beapotentialtherapeutictargetforcovid19